paishuning senaparib capsules ovarian cancer 20mg

Description

Indication & Scope

PaiShuNing® Senaparib Capsules treatsr adult patients with advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who achieve complete or partial remission after first-line platinum-based chemotherapy.

Mechanism: It is a selective PARP1 and PARP2 inhibitor, which blocks the DNA damage repair function of tumor cells with homologous recombination defects, causes synthetic lethality, and induces the apoptosis of cancer cells.
Drug class: Oral poly (ADP-ribose) polymerase inhibitor, anti-tumor prescription medicine.
Clinical use: It is used for maintenance treatment after platinum chemotherapy for ovarian, fallopian tube and primary peritoneal cancer to effectively prolong the progression-free survival period of patients.

Specification

Generic Name	Senaparib Capsules
Brand Name	PaiShuNing
Ingredient	Senaparib Capsules
Dosage Form	Capsules
Package	10mg100 capsules/box; 20mg75 capsules/box
Conditions Treated	Advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer
Taboos	Patients with severe allergic reactions to senaparib or preparation excipients; patients with a medical history of severe myelodysplastic syndrome or acute myeloid leukemia
Place of origin	China
Prescription type	Prescription-only
Storage Conditions	Store at 15°C to 30°C in a sealed environment to prevent moisture
Manufacturer	YingPai Pharmaceutical, Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	H20250002; H20250003
Approval Date	Jan 14, 2025
Shelf Life	24 months

How to use ?

Recommended Dose: 100mg taken orally once a day.

Time: Start medication within 8 weeks after the end of platinum-based chemotherapy, and take medicine continuously every day until disease progression or unmanageable toxic reactions occur.

Instructions for use: Take the capsule orally and swallow it whole. It can be taken with or without food, and no dose adjustment is required for patients with mild to moderate liver and kidney impairment.

Interaction: Moderate CYP3A4 inhibitors will increase the systemic exposure of senaparib, and strong CYP3A4 inducers will reduce the efficacy of the drug, so combined use is not recommended.

Side effects: Anemia, neutropenia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, elevated serum creatinine and headache.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is the main clinical use of Senaparib Capsules?

It serves as maintenance therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer after platinum-based chemotherapy.

What is the mechanism of Senaparib Capsules?

It selectively inhibits PARP1/2 enzymes, induces DNA repair defects, and causes synthetic lethality in homologous recombination-deficient tumor cells.

What are the most common side effects of Senaparib Capsules?

Typical adverse reactions include anemia, neutropenia, thrombocytopenia, fatigue, nausea, and elevated creatinine.

Who cannot take Senaparib Capsules clinically?

Patients with severe hypersensitivity and those with a history of myelodysplastic syndrome or acute myeloid leukemia are contraindicated.